Introduction
Faecal microbiota transplantation (FMT) is emerging as a promising therapy for inflammatory bowel diseases (IBD), with demonstrated benefits in ulcerative colitis (UC). Evidence for its efficacy in Crohn’s disease (CD) and mixed outcomes, depending on donor characteristics, highlight the need for improved treatment strategies. Diet is a major determinant of the gut microbiome and may modulate FMT efficacy.
Aims & Methods
Therefore, we aimed to investigate the independent and combined effects of dietary interventions and different FMT formulations, single‑donor, multidonor, and healthy multidonor, on disease activity in humanized preclinical UC and CD/ileitis mouse models.
Age- and sex‑matched SAMP (ileitis-prone) and C57BL/6 mice (ntot= 157; 4-8/ experimental group) were treated with broad‑spectrum antibiotics and humanized with respective patient-derived CD or UC microbiota. Animals were randomized to Western, Mediterranean, or control diets and received either healthy single‑donor FMT (only C57BL/6), multidonor FMT, or sham. After one week, acute colitis was induced using DSS (2%, 7 days), followed by 7 days of recovery. Disease activity indices (DAI) were assessed and analysed as AUC. Additional endpoints included microscopic inflammation scores. Faecal samples were collected longitudinally for 16S sequencing.
Results
Across both models, Mediterranean diet consistently reduced disease activity, whereas Western diet worsened outcomes (all P<0.05). Independent from diet, FMT improved disease activity in SAMP and C57BL/6 mice, though effects were donor‑dependent in the UC model. Donor 1 outperformed other single donors across all diets, whereas Donors 2, 3, and multidonor FMT showed variable, diet‑contingent responses. In SAMP mice, FMT decreased microscopic colitis severity (trend, P=0.073), but unexpectedly worsened ileitis (P=0.012). Mediterranean diet tended to reduce ileitis severity compared to Western diet (P=0.080). For the C57BL/6 mice, histologig inflammation scores tended to be higher for those on a Western diet (P=0.09). C57BL/6 mice showed reduced alpha diversity after antibiotic pretreatment (P<0.01), which restored after humanization, and was significantly higher in Mediterranean-fed mice after DSS recovery (P<0.01). Similar trends were observed after DSS recovery for Mediterranean-fed SAMP mice (p=0.078). No differences in alpha diversity were observed by FMT origin (P=0.91).
Conclusion
FMT and Mediterranean diet independently reduce disease activity in humanized IBD mouse models, with diet exerting strong microbiome‑modulating effects. FMT efficacy is donor-dependent in UC and exhibits site‑specific effects in ileitis-prone SAMP mice, ameliorating colitis, while potentially exacerbating ileitis. Further microbiome and mechanistic analyses are required to identify determinants of FMT success and to explain the divergent colonic versus ileal immune responses.